
Opdualag Misses Primary Endpoint in Phase III RELATIVITY-098 Trial for Melanoma
The Phase III RELATIVITY-098 trial (NCT05002569) of Opdualag (nivolumab and relatlimab-rmbw) in the adjuvant treatment of completely resected stage III-IV melanoma fell short of the primary endpoint of recurrence-free survival (RFS).1,2 Data regarding the …